Panthura
Panthura is developing targeted gene therapies for cystic fibrosis using a non-viral delivery system that can be administered systemically from the bloodstream to specific tissues. The platform is designed for long-lasting DNA expression and enables safe redosing, addressing the root cause of the disease for patients who are ineligible for or unresponsive to existing CFTR modulator therapies.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
Funding
Funding not disclosed
Founders
Founder details are not available yet.
Product
Problem
Cystic fibrosis remains a progressive, life-shortening genetic disease with limited treatment options that address the underlying cause. Current therapies, including CFTR modulators, are not effective for all patient genotypes and do not provide a durable, one-time correction of the defective gene, leaving a significant unmet medical need for a transformative approach.
Solution
Panthura is developing targeted gene therapies designed to address the root cause of cystic fibrosis by delivering functional DNA directly to affected cells. Their approach utilizes a non-viral delivery system that enables systemic administration from the bloodstream to specific tissues, ensuring the therapeutic gene reaches the intended site of action. The platform is engineered for long-lasting effects through sustained DNA expression, potentially reducing the need for frequent re-administration. Unlike viral vectors, the non-viral method allows for safe and effective redosing, which is critical for maintaining therapeutic benefit over time. The company is advancing its technology through rigorous pre-clinical studies, focusing on efficacy, safety, and translational readiness to bring a durable treatment option to patients.
Target Audience
Primary customers are patients with cystic fibrosis who are ineligible for or unresponsive to existing CFTR modulator therapies, as well as clinical partners and researchers focused on genetic disease treatments.
Features
- Non-viral delivery system designed for safe and repeat administration without the immunogenicity concerns of viral vectors
- Systemic delivery mechanism that targets specific tissues from the bloodstream, enabling broad biodistribution
- DNA-based therapeutic approach engineered for long-lasting, sustained gene expression in target cells
- Redosable platform capability, allowing for multiple treatment cycles to maintain or enhance therapeutic effect
- Pre-clinical pipeline focused on efficacy and safety validation, with architecture optimization for translational success